FDA expands indications of Esperion’s Nexletol and Nexlizet for heart attacks and LDL-C lowering
The label expansions are for the prevention of heart attacks and cardiovascular procedures in primary as well as…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Mar 24
The label expansions are for the prevention of heart attacks and cardiovascular procedures in primary as well as…
22 Mar 24
The FDA approval is supported by the results from EPIDYS, a randomized, double-blind, placebo-controlled 18-month Phase 3 clinical…
22 Mar 24
The positive CHMP opinion is based on results from the ONWARDS phase 3a clinical trial programme
21 Mar 24
The deal is anticipated to boost Lonza's large-scale biologics manufacturing capacity and will also help the firm cope…
19 Mar 24
The transaction complements AstraZeneca’s oncology portfolio with Fusion’s pipeline of RCs, including its lead programme FPI-2265, and replaces…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Mar 24
Sequel Pharma Executes Agreement with CDMO for Drug Substance Production
18 Mar 24
Xhance is a drug-device combination product that utilises the Exhalation Delivery System engineered to administer a topical steroid…
15 Mar 24
AstraZeneca said that the acquisition will further expand the pipeline of Alexion, AstraZeneca Rare Disease, beyond complement inhibition,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Mar 24
The FDA has approved Breyanzi to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small…
15 Mar 24
The approval was based on the results from the Phase 3 RATIONALE 302 study in which Tevimbra indicated…